• Hapvida clarified that media reports on “high double-digit” price hikes stem from its 2Q26 results materials filed on Aug. 12.
• About 947,000 beneficiaries, or 11% of its health-plan base, face commercial review due to weak profitability or delinquency.
• Contracts will be repriced case by case over the next 12 months at renewal dates, or discontinued if economics cannot be restored.
• “High double-digit” was described as a qualitative range, with intended average increases above broader portfolio levels, subject to negotiation.
• Hapvida said it has not quantified EBITDA impact, viewing any improvement as qualitative, with limited revenue exposure given lower ticket size.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hapvida Participações e Investimentos SA published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.